AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01341782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol placebo
Study NCT01341782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maxacalcitol placebo
Study NCT03261986 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiostereometric Analysis
Description: RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
Study NCT03261986 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: total hip arthroplasty with RSA bead implantation
Description: Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
Study NCT02293889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000IU/daily 3 months
Description: Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (>50nmol/L) by 3 months.
Study NCT02293889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA intervention People with Osteoarthritis Walking Programme
Description: The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
Study NCT02293889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule (Vitamin D): edible oil
Description: Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
Study NCT02235090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct current stimulation of cervical spinal cord
Description: 10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
Study NCT02235090 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Direct current stimulation of cervical spinal cord
Description: 10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
Study NCT06020287 — intervention group
Intervention type: PROCEDURE
Intervention: the robot-assisted laparoscopic radical prostatectomy
Description: We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
Study NCT04576299 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
Study NCT00460135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: 2 times a week resistance training
Study NCT03757260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy
Description: Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
Study NCT03757260 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of photodynamic therapy
Description: The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
Study NCT01425320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination dapsone/adapalene Formulation A Gel
Description: Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
Study NCT01425320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Combination dapsone/adapalene Formulation B Gel
Description: Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
Study NCT01425320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapsone 5% gel
Description: Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
Study NCT01425320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene 0.3% gel
Description: Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
Study NCT04258293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
Study NCT01083225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client feedback
Description: Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
Study NCT01083225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual, consultations
Study NCT00966680 — intervention group
Intervention type: OTHER
Intervention: Anesthesia
Description: How long anesthesiologists take to administer general and spinal anesthesia.
Study NCT01678313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
Description: Study group
Study NCT01678313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg every day (QD)
Description: Control group
Study NCT04831268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT04831268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentils and lupins mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Capillary glucose
Description: Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
Study NCT04831268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trahanas with tomato sauce mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03949361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy of supraclavicular adipose tissue (optional)
Description: Ultrasound guided biopsy of the supraclavicular adipose tissue
Study NCT01083368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT01083368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01083368 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT01083368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03971097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six Step Model of Self-Forgiveness
Description: The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process.
Study NCT04831268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halva with currants mixed meal
Description: Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03971097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
Study NCT03971097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
Study NCT01365013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DE-PLAN
Description: structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
Study NCT01365013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard advice for lifestyle change
Study NCT03478462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 131
Description: IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Study NCT04419662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect.
Study NCT04419662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of PEEP and positioning
Description: Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees.
Study NCT02204397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INGAP Peptide, Ustekinumab
Study NCT00678236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refobacin Bone Cement R
Description: Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
Study NCT00678236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refobacin Plus Bone Cement
Description: Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
Study NCT04314609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography, fluoroscopy
Description: success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
Study NCT00804674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacain
Study NCT00804674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01516437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
Study NCT01516437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swab collection
Description: Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
Study NCT01516437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum collection
Description: Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
Study NCT00217620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 800 mg per day, daily until progression
Study NCT01622504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVP005
Description: 2 mg single dose administered intranasally
Study NCT02892305 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic Resection or Ablation with Pancreaticoduodenectomy
Description: Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care.
Study NCT00997555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopy
Description: Scheduled bronchoscopy.
Study NCT01622504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVP005
Description: 4 mg single dose administered intranasally
Study NCT01622504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride solution for injection with mucosal atomization device
Description: 2 mg single dose administered intranasally
Study NCT01535547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral
Study NCT01535547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT03281577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 IV infusion.
Study NCT01398215 — intervention group
Intervention type: PROCEDURE
Intervention: transvaginal NOTES ventral hernia repair
Description: ventral hernia repair via the transvaginal approach
Study NCT03281577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-954 placebo-matching IV infusion.
Study NCT01709513 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Atorvastatin over-encapsulated tablets.
Study NCT01709513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe over-encapsulated tablet.
Study NCT01709513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study NCT01709513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for alirocumab, ezitimibe and atorvastatin.
Study NCT01709513 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo for alirocumab, ezitimibe and atorvastatin.
Study NCT01709513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for alirocumab, ezitimibe and atorvastatin.
Study NCT04460365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin
Description: This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood.
Study NCT04460365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel capsule containing sunflower oil (no active ingredients)
Study NCT03465046 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intensive therapies(CIMT/BIT): protocol 1 or protocol 2
Description: The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family
Study NCT00606177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg(4 tablets)/day
Study NCT00606177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 0mg(4tablets)/day
Study NCT03674567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: IV infusion
Study NCT02259946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL
Study NCT02259946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02259946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Study NCT02152150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron bio-fortified pearl millet
Description: Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
Study NCT02152150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control pearl millet
Description: Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
Study NCT02314598 — intervention group
Intervention type: OTHER
Intervention: No treatment
Study NCT02653352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
Study NCT02814136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Study NCT01810874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Study NCT01810874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Study NCT00313157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Study NCT00313157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Study NCT00313157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Study NCT00313157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Study NCT01472302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation
Description: Ventilation protocol according to the patients ideal body weight
Study NCT01472302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Controlled Ventilation
Description: Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
Study NCT02781831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehab
Description: Standard hospital based rehabilitation for patients with stroke
Study NCT02781831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait rehabilitation
Description: An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke